Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
PERI
SLSBio (Specialty Lab Solution Bio)
★★★

SLSBio Quarterly Report: Revenue Plunges 45%, Operating Loss Widens, Listing Eligibility Review Poses Risk to Shareholder Value

  06/02/2026, 10:31 AM
PERI
SLSBio (Specialty Lab Solution Bio)
★★★

SLS Bio: Q1 2026 Operating Loss of KRW 950M, Under Listing Eligibility Review

  05/15/2026, 02:34 PM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.